Ariad S, Bezwoda W R
Department of Medicine, University of the Witwatersrand Medical School, Johannesburg, South Africa.
Isr J Med Sci. 1992 Jun;28(6):377-85.
The steep dose-response curve for most chemotherapeutic drugs and the need to overcome tumor resistance has resulted in renewed interest in the use of high-dose chemotherapy. Bone marrow rescue has allowed the dose-limiting barrier of hematopoietic suspension to be overcome. However, despite such salvage methods and the use of blood products and effective antibiotics, myelosuppression remains a major obstacle to treatment. The use of recombinant colony-stimulating factors in combination with bone marrow following high-dose chemotherapy may well shorten the period of neutropenia and reduce the frequency of neutropenia-related complications, thus making high-dose treatment more acceptable.
大多数化疗药物陡峭的剂量反应曲线以及克服肿瘤耐药性的需求，使得人们对高剂量化疗的应用重新产生了兴趣。骨髓救援使得造血抑制这一剂量限制障碍得以克服。然而，尽管有此类挽救方法以及血液制品和有效抗生素的使用，骨髓抑制仍然是治疗的一个主要障碍。高剂量化疗后将重组集落刺激因子与骨髓联合使用，很可能会缩短中性粒细胞减少期，并降低中性粒细胞减少相关并发症的发生率，从而使高剂量治疗更易被接受。
